20 Background aims: Delaying replicative senescence and extending lifespan of human mesenchymal stromal cells (MSCs) may enhance their potential for tissue engineering 22 and cell based therapies. Accumulating evidence suggests that inhibitors of the mTOR signaling pathway, such as rapamycin, constitute promising pharmacological agents to 24 retard senescence and extend stemness properties of various progenitor cell types. Here, we investigated whether the ability of rapamycin to postpone replicative senescence 26 varies among bone marrow MSC samples (BM-MSCs) derived from different healthy donors, and explored the molecular mechanisms that drive rapamycin-mediated lifespan 28 increment. Methods: BM-MSCs at early passages were serially passaged either in absence or 30 continuous presence of rapamycin and the number of cell population doublings until growth arrest was measured. The inhibition of mTOR signaling was assessed by the 32 phosphorylation status of the downstream target RPS6. The expression levels of several senescence and pluripotency markers at early and late/senescent passages were analyzed 34 by RT-qPCR, flow cytometry and western blot. Results: We found that the lifespan extension in response to the continuous rapamycin 36 treatment was highly variable among samples, but effective in most BM-MSCs. Despite all rapamycin-treated cells secreted significantly reduced levels of IL6, a major SASP 38 cytokine, and expressed significantly higher levels of the pluripotency marker NANOG, the expression patterns of these markers were not correlated with the rapamycin-40 mediated increase in lifespan. Interestingly, rapamycin-mediated life-span extension was significantly associated only with repression of p16 INK4A protein accumulation. 42 Conclusions: Taken together, our results suggest that some, but not all, BM-MSC samples would benefit from using rapamycin to postpone replicative arrest and 44 reinforce a critical role of p16 INK4A protein downregulation in this process. 46 Key words: Cellular senescence, mesenchymal stromal cells, mTOR signaling, rapamycin, senescence and pluripotency markers, p16 INK4A protein expression.
Introduction 50
In recent years, there has been increasing evidence that persistent activation of the growth-promoting mammalian target of rapamycin (mTOR) pathway plays a central 52 role in cellular senescence and organismal aging [1] [2] [3] , representing a key molecular driver of stem cell depletion and reduced tissue regenerative capacity [4] [5] [6] . Importantly, 54 attenuation of mTOR signaling with rapamycin seems to preserve the clonogenic ability and function, besides delaying the activation of senescence mechanisms, in mouse and 56 human stem cells from various tissues, including hematopoietic [5, 7, 8] , epithelial [6, 9] , spermatogonial [10] and mesenchymal stem cells [11] .
58
The mechanisms by which mTOR inhibition protects from stem cell exhaustion and aging have been associated with reduced accumulation of cytoplasmic and/or 60 mitochondrial reactive oxygen species [6, 7, 11] and DNA damage [6, 9, 11] , decreased secretion of major senescence-associated cytokines [6] and reduced expression of tumor 62 suppressors such as p16 INK4A [6, 11] . Moreover, the rapamycin-induced persistent expression of pluripotency genes, such as NANOG and OCT4 [11] , has been suggested 64 to contribute to the retention of stemness properties of stem cells.
The possibility of retarding senescence and extending stemness properties of in 66 vitro expanded mesenchymal stromal cells (MSCs) is particularly relevant to regenerative medicine, as replicative senescence might limit the number of cells 68 required for clinical use [12, 13] . In a previous study, using long-term MSC cultures, we have shown that bone marrow MSCs (BM-MSCs) isolated from healthy young donors 70 display variable in vitro replicative potential until reaching senescence and ceasing to proliferate [14] . Also, we documented that those BM-MSC samples with lower 72 expression of the senescence marker p16 INK4A and higher expression of the pluripotency marker OCT4 at early passages present greater replicative lifespan [14] . Although 74 rapamycin has been shown to decelerate cell senescence in different experimental models, such as radiation and replicative induced senescence, no study has evaluated 76 the effects of long-term treatment of BM-MSC samples endowed with variable replication capabilities with rapamycin. These observations prompted us to ask whether 78 the ability of rapamycin to postpone replicative senescence varies among individual BM-MSC samples and to investigate the molecular players involved in lifespan 80 extension mediated by mTOR inhibition in this long-term cell culture model. To examine whether the observed lifespan extension is rapamycin-dependent, 112 rapamycin was withdrawn from BM09 cells during the exponential phase of growth and cells were cultured in rapamycin-free medium until proliferative arrest. After this, 114 quiescent cells were cultured again in culture medium containing rapamycin (20nM). Fig 1A) . Also, we observed that the PDT of most samples treated with 194 rapamycin remains significantly more constant for a longer period over the course of serial passages compared to the corresponding untreated cells, and this effect is most 196 evident for BM09, which showed the greater lifespan extension promoted by rapamycin ( Fig 1B) . This important effect on BM09 lifespan was mediated by the continuous 198 presence of rapamycin, as these cells lose their proliferative potential few passages after rapamycin removal and returned to active proliferation after replacement of the drug in 200 culture medium ( Fig 1C) , suggesting that the cells achieved the quiescent state and retained the capacity to resume proliferation upon mTOR inhibition. Finally, we observed that despite the fact that all rapamycin-treated samples progress towards growth arrest, cells continued to respond to rapamycin along the entire 222 lifespan, as assessed by the phosphorylation status of ribosomal protein S6 (RPS6), a downstream target of the mTOR pathway (Fig 2) , which may suggest that mTOR- , the secretion of cytokines IL6 and IL8, and the expression of pluripotency genes OCT4 and NANOG in 278 rapamycin-treated and untreated cells at passages when untreated cells entered into a state of proliferative arrest (referred to as the "deviation passage", as depicted in Fig 1) .
Results

280
We observed that whereas rapamycin exerted no significant effect on p16 INK4A mRNA expression, it decreased p16 INK4A protein expression in BM09, BM13, BM16 282 and BM18, but had no effect on the expression of this protein in BM12 ( Fig 3A) .
Therefore, due to the lack of effect of mTOR inhibition on p16 
286
Although all rapamycin-treated samples showed, as expected, decreased secretion of IL6 and IL8 compared to the corresponding untreated cells, only the effect 288 of mTOR inhibition on IL6 secretion reached statistical significance (p0.05) ( Fig 3B) .
This lack of significance may be probably due to the highly variable IL8 secretion 290 among samples. Finally, we observed that cells expanded in the presence of rapamycin showed significant increased expression levels of NANOG (p<0.05) ( Fig 3C) . The 292 rapamycin-mediated significant decrease in the secretion of a major SASP cytokine and increase in the expression of NANOG may contribute to cell proliferation at a relatively 294 more constant rate (less variable PDT, Fig 1B) over an extended period in culture and retention of the non-senescent phenotype of MSCs. 328 levels, the greater the rapamycin extended lifespan (Fig 4) . These results suggest that the ability of rapamycin in inhibiting p16 INK4A accumulation, rather than inhibiting IL6 330 and IL8 secretion and stimulating NANOG expression, during serial passages is tightly associated with the MSC replicative lifespan extension. in rapamycin-treated cells that ceased to proliferate (at the "senescent passage with rapamycin") are slightly greater than those observed in the 348 "deviation passage with rapamycin" (Fig 5) , suggesting that the slight increase in p16 INK4A accumulation may contribute to the cessation of rapamycin-treated cell 350 proliferation, but that other molecular events might also be required to induce final growth arrest of rapamycin-treated cells. have shown that mTOR inhibition by rapamycin can delay the progression of stem cell 386 senescence [6, 11] . However, results of our study provide evidence for the benefits of mTOR inhibition in long-term MSC expansion and also, for the first time, alert for 388 marked interindividual variability in the response to rapamycin, suggesting that its use might benefit expansion of some cells, not all BM-MSCs.
390
The identification of reliable early predictors of stem cell lifespan extension in response to mTOR inhibition would be valuable for regenerative medicine and cellular 392 therapy. However, none of the six classical senescence-associated proteins and the three pluripotent-related genes expressed by early-passage BM-MSCs evaluated here were 394 useful predictors of rapamycin-mediated lifespan prolongation, as no correlation could be established.
396
To characterize important players involved in rapamycin-mediated postponement of replicative senescence of BM-MSCs in our model, we analyzed the 398 expression levels of known senescence-and pluripotency-related markers in rapamycintreated and untreated cells at the passage when untreated cells stop proliferating 400 (become senescent) and the corresponding rapamycin-treated cells still displayed proliferation capacity. Our results showed that, as observed in other models of cellular 402 senescence, rapamycin-treated cells secreted significantly reduced levels of a major SASP cytokine (IL6), which is known to act in an autocrine manner to reinforce the cell 404 cycle arrest of senescent cells [6, 18] , and expressed significantly increased levels of NANOG, a marker/inducer of pluripotency and cellular clonogenicity [11, 19, 20] .
406 Therefore, although we have not evaluated the clonogenic and differentiation capacity of rapamycin-treated BM-MSCs, the diminished secretion of IL6 and elevated 408 expression of NANOG may confer stemness properties to rapamycin-treated BM-MSCs, such as the observed cell PD at a relatively more constant rate. However, the expression 410 patterns of these two markers were not correlated with the rapamycin-mediated increase in the replicative capacity of each sample, suggesting that other molecular triggers are 412 involved in this process. 
